DGAP-News

Biotest AG: Biotest completes recruitment in Phase IIb study (TREAT 2b) of Tregalizumab (BT-061) in patients with rheumatoid arthritis - Seite 2

data from the main part of TREAT 2b will be the basis for start of Phase
III clinical development.


About Tregalizumab (BT-061)
Tregalizumab (BT-061) is a humanized monoclonal anti-CD4 antibody, which
selectively activates regulatory T cells (Tregs). Tregalizumab (BT-061)
thereby strengthens a natural function of the body that prevents excessive
immune reactions. The antibody is being developed to treat diseases due to
an overreaction of the immune system such as autoimmune diseases.
Tregalizumab (BT-061) is currently in Phase IIb clinical development for
rheumatoid arthritis.

About rheumatoid arthritis
Rheumatoid arthritis (RA) is a progressive inflammatory autoimmune disease
that affects joints and organs. It is estimated that about 5 million people
worldwide suffer from RA, with between 0.3 % and 1 % of the population of
industrialized countries affected. The disease occurs three times more
often in women than in men. Although RA can affect people of all age
groups, the disease in most cases occurs between the ages of 40 and 60
years. Traditional treatment methods against rheumatoid arthritis include
nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids and
disease-modifying antirheumatic drugs (DMARDs). Treatments based on
biotechnology preparations have been added recently.

Disclaimer

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of rheumatoid arthritis and cancer of plasma cells, which are